US IPO Pipeline SEC S-1 Filings — May 19, 2026

19-05-2026

Lawaken Group Inc. filed an S-1 registration statement with the SEC on May 19, 2026, detailing its proposed initial public offering. The filing includes executive compensation data for 2024 and 2025, showing CEO Ru Yi's total compensation rose significantly from $293,250 in 2024 to $1,851,564 in 2025, driven by large option awards. However, the company currently provides no retirement, health or welfare benefits to any employees and had no director compensation in 2024, indicating a nascent stage of corporate infrastructure.

• · CEO Ru Yi's salary increased from $42,000 in 2024 to $69,584 in 2025, with employment agreement providing future base salary of $150,000/yr from Jan 1, 2026.
• · CFO Zhang Zhenliu is part-time (50% business time) and his employment is at-will with a 60-day notice period; he received no bonus or option awards in 2024.
• · COO Zhang Jianhua began employment May 1, 2025 and his consulting agreement includes a 3.5% commission on wholesale sales; he also has a $50,000 bonus tied to an $8M sales quota.
• · No director cash or equity compensation was paid in fiscal 2024; post-IPO director retainers range from $5,000/yr to $30,000/yr.
• · The company does not provide retirement, health, or welfare benefits to any employees.
• · Directors and officers will be indemnified to the fullest extent permitted by Florida law; D&O insurance will be obtained prior to IPO closing; no pending or threatened indemnification claims exist.
• · Multiple stock option grants in July-August 2025 were made under the 2025 Equity Incentive Plan; two performance-based grants vest upon completion of an $8M sales quota or an acquisition/flotation at ≥400% of the 2024 annual valuation ($2.7M).
• · There are minor discrepancies in the filing: footnote (1) describes 375,000 options for FY2024 and footnote (2) 700,000 options for FY2025, but the Outstanding Equity Awards table shows 187,500+0+11,108 exercisable (none for the 700,000 grant) and 187,500+600,000+88,892 unexercisable for Ru Yi.

19-05-2026

Parabilis Medicines, Inc. filed an S-1 registration statement on May 19, 2026, for an initial public offering of common stock on the Nasdaq Global Market under the symbol 'PBLS'. The company plans to concurrently raise $75.0 million from Regeneron in a private placement at 90% of the IPO price. Net losses widened from $117.9 million in FY2024 to $145.9 million in FY2025, and from $38.3 million in Q1 2025 to $45.3 million in Q1 2026, driven by rising R&D and G&A expenses.

• · The company has an accumulated deficit of $586.8 million as of March 31, 2026.
• · Total stockholders' deficit was $570.3 million as of March 31, 2026.
• · Convertible preferred stock stood at $814.5 million as of March 31, 2026.
• · Net loss per share allocable to common stockholders worsened from $(54.25) in FY2024 to $(60.04) in FY2025, and from $(15.49) in Q1 2025 to $(22.47) in Q1 2026.
• · Sublease income from related party dropped to zero in Q1 2026 from $1.1 million in Q1 2025.
• · Interest income declined 47.2% year-over-year from FY2024 to FY2025, but increased 93.2% quarter-over-quarter from Q1 2025 to Q1 2026.
• · The company has a SAFE agreement of $50.0 million that will convert into common stock at the IPO price.
• · The concurrent private placement with Regeneron is for $75.0 million at 90% of the IPO price and is contingent on the IPO closing, but the IPO is not contingent on the private placement.

19-05-2026

Cellectar Biosciences, Inc. filed an S-1 registration statement with the SEC on May 19, 2026, for a proposed public offering of securities. The filing includes exhibits related to the company's capital stock, warrants, and material agreements, but does not disclose the number of shares or the proposed offering price. The registration statement is preliminary and subject to SEC review.

• · The filing includes exhibits for multiple series of preferred stock (Series D, Series E) and various warrants (Tranche A, Tranche B, Series I, Series II, Common Stock Purchase Warrants A/B/C).
• · The registration statement incorporates by reference the company's annual report on Form 10-K filed on March 13, 2025.
• · The filing includes a consent from Deloitte & Touche LLP, the independent registered public accounting firm.
• · The company has a history of multiple amendments to its certificate of incorporation and various equity financing transactions dating back to 2011.

19-05-2026

JAB Acquisition Corp I, a blank check company, filed an S-1 registration statement on May 19, 2026, for an initial public offering of 15,000,000 units at $10.00 per unit, with each unit consisting of one Class A ordinary share, one redeemable warrant, and one right to receive one-fourth of a Class A share. The company has not yet selected a business combination target but intends to focus on technology, healthcare, and logistics industries with an enterprise value of $150 million or greater. The offering includes a 45-day over-allotment option for up to 2,250,000 additional units, and the sponsor has committed to purchasing 260,000 private units for $2,600,000.

• · The company is incorporated in the Cayman Islands and classified as a blank check company (SIC 6770).
• · Warrants become exercisable 12 months from the date of the prospectus or upon completion of the initial business combination, whichever is later, and expire five years after the business combination.
• · Each right entitles the holder to receive one-fourth of one Class A ordinary share upon consummation of an initial business combination.
• · The sponsor purchased 9,857,143 Class B founder shares for $25,000 ($0.002 per share) on March 19, 2026.
• · If the over-allotment option is not exercised, up to 1,285,714 founder shares will be surrendered so the sponsor owns 35% of outstanding ordinary shares post-offering.
• · The company has 12 months from closing to complete a business combination, extendable by up to two three-month periods with a $0.10 per share deposit each time.
• · Shareholders can vote to further extend the completion window with no limit on the number of extensions.
• · Public shareholders have redemption rights upon completion of the initial business combination, but a single shareholder (with affiliates) is limited to redeeming no more than 15% of the shares sold in the offering without company consent.
• · The company has not initiated any substantive discussions with any business combination target.

19-05-2026

Arterior Solutions Corp, a development-stage interior/exterior design company, has filed an S-1 registration statement to offer 9,000,000 shares of common stock at $0.02 per share in a self-underwritten best-efforts offering, with no minimum purchase requirement. The company has not commenced substantive revenue-generating operations, reported a net loss of $404 since inception (June 23, 2025 through April 30, 2026), and its independent auditor has expressed substantial doubt about its ability to continue as a going concern. Existing stockholders Mira Palic and Goran Radosavljevic will retain majority control unless all shares are sold, and no public market currently exists for the stock.

• · The company was incorporated in Wyoming on June 23, 2025.
• · If fewer than 8,800,000 shares are sold in this offering, existing stockholders will continue to own a majority of outstanding shares.
• · The offering is being conducted on a self-underwritten best-efforts basis without underwriters or broker-dealers; Mira Palic will rely on the safe harbor from broker-dealer registration under Rule 3a4-1.
• · No minimum purchase requirement exists for the offering to proceed, and the company will retain proceeds from any shares sold.
• · The company is an 'emerging growth company' under the JOBS Act and has elected not to use the extended transition period for new accounting standards.
• · The company stated it is not a Blank Check company and has no plans for a merger or acquisition.